Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Century Therapeutics, Inc. (IPSC)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 54,820,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Century Therapeutics is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. Co.'s primary product candidate, CNTY-101, is an allogeneic, chimeric antigen receptors (CAR)-induce pluripotent stem cell-derived (iPSC-derived) natural killer (iNK) cell therapy that has been engineered to express CD19 CAR, soluble IL-15, an epidermal growth factor receptor safety switch, and also contains gene edits needed to incorporate Allo-Evasion™ technology. CNTY-103 is Co.'s main product candidate targeting a solid tumor.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 64,019 64,019 64,019 1,123,730
Total Sell Value $308,320 $308,320 $308,320 $8,014,809
Total People Sold 3 3 3 5
Total Sell Transactions 8 8 8 13
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 52
  Page 1 of 3  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Russotti Gregory See Remarks   •       –      –    2024-04-22 4 AS $3.10 $15,490 D/D (5,000) 297,319     -
   Pfeiffenberger Brent President and CEO   •       •      –    2024-03-07 4 A $0.00 $0 D/D 17,425 1,470,704     -
   Farid Adrienne Chief Operations Officer   •       –      –    2024-03-07 4 A $0.00 $0 D/D 24,000 138,149     -
   Levitsky Hyam President of R&D   •       –      –    2024-03-07 4 A $0.00 $0 D/D 24,000 24,000     -
   Carr Douglas SVP Finance & Operations   •       –      –    2024-03-07 4 A $0.00 $0 D/D 14,000 317,580     -
   Russotti Gregory See Remarks   •       –      –    2024-03-07 4 A $0.00 $0 D/D 24,000 302,319     -
   Farid Adrienne Chief Operations Officer   •       –      –    2024-03-07 4 AS $5.14 $117,342 D/D (22,831) 114,149     -
   Farid Adrienne Chief Operations Officer   •       –      –    2024-03-07 4 OE $1.03 $23,516 D/D 22,831 136,980     -
   Farid Adrienne Chief Operations Officer   •       –      –    2024-03-06 4 AS $4.96 $152,340 D/D (30,684) 114,149     -
   Farid Adrienne Chief Operations Officer   •       –      –    2024-03-06 4 OE $1.03 $31,605 D/D 30,684 144,833     -
   Farid Adrienne Chief Operations Officer   •       –      –    2024-02-16 4 AS $4.86 $2,358 D/D (485) 114,149     -
   Farid Adrienne Chief Operations Officer   •       –      –    2024-02-16 4 OE $1.03 $500 D/D 485 114,634     -
   Farid Adrienne Chief Operations Officer   •       –      –    2024-02-06 4 S $4.49 $8,005 D/D (1,784) 114,149     -
   Carr Douglas SVP Finance & Operations   •       –      –    2024-02-06 4 S $4.49 $2,499 D/D (557) 303,580     -
   Farid Adrienne Chief Operations Officer   •       –      –    2024-02-05 4 S $3.84 $7,816 D/D (2,035) 115,933     -
   Carr Douglas SVP Finance & Operations   •       –      –    2024-02-05 4 S $3.84 $2,470 D/D (643) 304,137     -
   Pfeiffenberger Brent President and CEO   •       •      –    2023-12-04 4 A $0.00 $0 D/D 1,453,279 1,453,279     -
   Diem Michael Craig Chief Financial Officer   •       –      –    2023-05-15 4 A $0.00 $0 D/D 151,058 274,296     -
   Carr Douglas SVP Finance & Operations   •       –      –    2023-05-15 4 A $0.00 $0 D/D 120,846 321,391     -
   Levitsky Hyam President of R&DOfficer   •       –      –    2023-04-12 3 IO $0.00 $0 I/I 0 536,544     -
   Borges Luis Chief Scientific Officer   •       –      –    2023-04-03 4 OE $1.03 $7,676 D/D 7,452 256,535     -
   Borges Luis Chief Scientific Officer   •       –      –    2023-03-23 4 S $3.55 $55,369 D/D (15,597) 249,083     -
   Borges Luis Chief Scientific Officer   •       –      –    2023-03-23 4 OE $1.03 $227,558 D/D 220,930 264,680     -
   Borges Luis Chief Scientific Officer   •       –      –    2023-03-22 4 S $3.72 $244,640 D/D (65,698) 43,750     -
   Borges Luis Chief Scientific Officer   •       –      –    2023-03-22 4 OE $1.03 $67,669 D/D 65,698 109,448     -
  52 Records found
  1  2  3   
  Page 1 of 3
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us